Two New Drugs Added to Heart Failure Clinical Practice Guideline

Share this content:
Two New Drugs Added to Heart Failure Clinical Practice Guideline
Two New Drugs Added to Heart Failure Clinical Practice Guideline

MONDAY, May 23, 2016 (HealthDay News) -- An updated clinical guideline adds two new types of drugs to the list of treatment options for heart failure. The updated guideline was published online May 20 in the Journal of the American College of Cardiology, Circulation, and the Journal of Cardiac Failure.

The two new treatments in the updated guideline are an angiotensin receptor-neprilysin inhibitor (valsartan/sacubitril), sold as Entresto, and a sinoatrial node modulator (ivabradine), sold as Corlanor, according to the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America.

Previously recommended drugs for these patients include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers, and diuretics.

"Treatment options for patients with heart failure have expanded considerably. There is more hope than ever before for patients with heart failure," guideline update committee vice chair Mariell Jessup, M.D., of the University of Pennsylvania School of Medicine in Philadelphia, said in a news release from the heart groups. "These guideline recommendations will serve as a tool to guide the choice of therapy and, in turn, improve outcomes."

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »